Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Research & Development

Product Pipeline

Targeted Approach To

Rare Diseases

News & Events

Proteus Syndrome Treatment

ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies

ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases

More News & Events »